Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium, 5250 [2021-01051]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
5250
Federal Register / Vol. 86, No. 11 / Tuesday, January 19, 2021 / Notices
filed by Universal Electronics, Inc.
(‘‘UEI’’) of Scottsdale, Arizona. 85 FR
31211–212 (May 22, 2020). The
complaint, as supplemented, alleges
violations of section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C. 1337
(‘‘Section 337’’), in the importation into
the United States, sale for importation,
or sale in the United States after
importation of certain electronic
devices, including streaming players,
televisions, set top boxes, remote
controllers, and components thereof, by
reason of infringement of one of more of
the asserted claims of the ’196 patent
and U.S. Patent No. 7,696,514 (‘‘the ’514
patent’’); 9,911,325 (‘‘the ’325 patent’’);
7,589,642 (‘‘the ’642 patent’’);
10,600,317 (‘‘the ’317 patent’’); and
9,716,853 (‘‘the ’853 patent’’). Id. The
complaint also alleges that a domestic
industry exists. Id. The Commission’s
notice of investigation named the
following respondents: Roku Inc. of Los
Gatos, California; TCL Electronics
Holdings Ltd. of New Territories, Hong
Kong; Shenzhen TCL New Technology
Co. Ltd. of Shenzhen, China; TCL King
Electrical Appliances Co. Ltd., Huizhou,
China; TTE Technology Inc. of Corona,
California; TCL Corp. of Huizhou City,
China; TCL Moka Int’l Ltd. of New
Territories, Hong Kong; TCL Overseas
Marketing Ltd. of New Territories, Hong
Kong; TCL Industries Holdings Co., Ltd.
of New Territories, Hong Kong; TCL
Smart Device Co. of Bac Tan Uyen
District, Vietnam; Hisense Co. Ltd. of
Qingdao, China; Hisense Electronics
Manufacturing Co. of America Corp. of
Suwanee, Georgia; Hisense Import &
Export Co. Ltd. of Qingdao, China;
Qingdao Hisense Electric Co., Ltd. of
Qingdao, China; Hisense International
Co., Ltd. of Shen Wang, Hong Kong;
Funai Electric Co., Ltd. of Osaka, Japan;
Funai Corp. Inc. of Rutherford, New
Jersey; and Funai Co., Ltd. of Nakhon
Ratchasima, Thailand (collectively,
‘‘Respondents’’). Id. The Office of Unfair
Import Investigations is not
participating in this investigation. Id.
The Commission previously
terminated the investigation with
respect to the ’853 patent, claims 19 and
20 of the ’196 patent, and claims 14 and
20 of the ’642 patent due to the
withdrawal of those patent claims.
Order No. 27 at 1 (Dec. 2, 2020),
unreviewed by Comm’n Notice (Dec. 23,
2020). The Commission subsequently
terminated the investigation with
respect to claim 20 of the ’514 patent.
Order No. 32 (Dec. 21, 2020),
unreviewed by Comm’n Notice (Jan. 5,
2021).
On December 29, 2020, the presiding
administrative law judge issued the
subject ID (Order No. 33), granting a
VerDate Sep<11>2014
19:19 Jan 17, 2021
Jkt 253001
joint motion by UEI and Respondents to
correct the notice of institution of the
investigation by clarifying that claims 2
and 4–5 of the ’196 patent are domestic
industry claims only and are not being
asserted against any Respondent for
purposes of infringement.
No petition for review of the subject
ID was filed.
The Commission has determined not
to review the subject ID. The notice of
institution of the investigation is
corrected accordingly.
The Commission vote for this
determination took place on January 13,
2021.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: January 13, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–01083 Filed 1–15–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Medical CBRN Defense
Consortium
Notice is hereby given that, on
January 8, 2021, pursuant to Section 6(a)
of the National Cooperative Research
and Production Act of 1993, 15 U.S.C.
4301 et seq. (‘‘the Act’’), Medical CBRN
Defense Consortium (‘‘MCDC’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
Aldevron, LLC, Fargo, ND; Applied
Nanotech, Inc., Austin, TX; Clark Street
Associates, Los Altos, CA; Encryptor,
Inc., Plano, TX; Entasis Therapeutics,
Waltham, MA; ImmunityBio, Inc., El
Segundo, CA; Polaris Sensor
Technologies, Huntsville, AL; Qorvo
Biotechnologies, LLC, Bend, OR; Rigel
Pharmaceuticals, San Francisco, CA;
SafetySpect, Inc., Los Angeles, CA; and
Somnio Global, LLC, Novi, MI have
been added as parties to this venture.
Also, 7 Hills Pharma, LLC, Houston,
TX; ARMSTEL, Inc., Plano, TX; Captura
PO 00000
Frm 00121
Fmt 4703
Sfmt 4703
Biopharma, Inc., Little Rock, AR;
Chenega Reliable Services, LLC, San
Antonio, TX; Data Intelligence
Technologies, Inc., Arlington, VA;
DEFTEC Corporation, Huntsville, AL;
HDT Bio Corporation, Seattle, WA; MAE
Group, LLC, Deerfield, NH; Metabiota,
Inc., San Francisco, CA; Microscale
Devices, LLC, Apex, NC; One Health
Group, LLC, Chantilly, VA; Pathology
Assist-Temp, Inc., Chantilly, VA;
Peregrine Technical Solutions, LLC,
Yorktown, VA; Profectus BioSciences,
Inc., Baltimore, MD; TensorX, Inc.,
Vienna, VA and the University of
Michigan, Ann Arbor, MI have
withdrawn as parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and MCDC
intends to file additional written
notifications disclosing all changes in
membership.
On November 13, 2015, MCDC filed
its original notification pursuant to
Section 6(a) of the Act. The Department
of Justice published a notice in the
Federal Register pursuant to Section
6(b) of the Act on January 6, 2016 (81
FR 513).
The last notification was filed with
the Department on October 20, 2020. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on November 20, 2020 (85 FR
74386).
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
[FR Doc. 2021–01051 Filed 1–15–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Countering Weapons of
Mass Destruction
Notice is hereby given that, on
January 7, 2021, pursuant to Section 6(a)
of the National Cooperative Research
and Production Act of 1993, 15 U.S.C.
4301 et seq. (‘‘the Act’’), Countering
Weapons of Mass Destruction
(‘‘CWMD’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
E:\FR\FM\19JAN1.SGM
19JAN1
]]>Agencies
[Federal Register Volume 86, Number 11 (Tuesday, January 19, 2021)]
[Notices]
[Page 5250]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01051]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Medical CBRN Defense Consortium
Notice is hereby given that, on January 8, 2021, pursuant to
Section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense
Consortium (``MCDC'') has filed written notifications simultaneously
with the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Aldevron, LLC, Fargo, ND; Applied Nanotech, Inc., Austin,
TX; Clark Street Associates, Los Altos, CA; Encryptor, Inc., Plano, TX;
Entasis Therapeutics, Waltham, MA; ImmunityBio, Inc., El Segundo, CA;
Polaris Sensor Technologies, Huntsville, AL; Qorvo Biotechnologies,
LLC, Bend, OR; Rigel Pharmaceuticals, San Francisco, CA; SafetySpect,
Inc., Los Angeles, CA; and Somnio Global, LLC, Novi, MI have been added
as parties to this venture.
Also, 7 Hills Pharma, LLC, Houston, TX; ARMSTEL, Inc., Plano, TX;
Captura Biopharma, Inc., Little Rock, AR; Chenega Reliable Services,
LLC, San Antonio, TX; Data Intelligence Technologies, Inc., Arlington,
VA; DEFTEC Corporation, Huntsville, AL; HDT Bio Corporation, Seattle,
WA; MAE Group, LLC, Deerfield, NH; Metabiota, Inc., San Francisco, CA;
Microscale Devices, LLC, Apex, NC; One Health Group, LLC, Chantilly,
VA; Pathology Assist-Temp, Inc., Chantilly, VA; Peregrine Technical
Solutions, LLC, Yorktown, VA; Profectus BioSciences, Inc., Baltimore,
MD; TensorX, Inc., Vienna, VA and the University of Michigan, Ann
Arbor, MI have withdrawn as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and MCDC intends to file additional
written notifications disclosing all changes in membership.
On November 13, 2015, MCDC filed its original notification pursuant
to Section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to Section 6(b) of the Act on
January 6, 2016 (81 FR 513).
The last notification was filed with the Department on October 20,
2020. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on November 20, 2020 (85 FR 74386).
Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2021-01051 Filed 1-15-21; 8:45 am]
BILLING CODE P
